Newly FDA Approved Device to Treat Urinary and Bowel Dysfunction Now Available in Quincy

Quin­cy Med­ical Group is now offer­ing Axon­ics® Ther­a­py — the first recharge­able neu­rostim­u­la­tion device that pro­vides a long-last­ing solu­tion to help patients gain control.

QUIN­CY, IL – Quin­cy Med­ical Group (QMG) Urol­o­gist Matthew Knud­son, M.D. recent­ly announced the addi­tion of Axon­ics Ther­a­py — a long-last­ing and clin­i­cal­ly proven solu­tion that pro­vides symp­tom relief for patients suf­fer­ing with over­ac­tive blad­der, bow­el incon­ti­nence, and uri­nary reten­tion. Mil­lions of peo­ple world­wide suf­fer from these chron­ic and debil­i­tat­ing symp­toms.¹

Dr. Knud­son will host a vir­tu­al com­mu­ni­ty health talk titled ​“Regain Blad­der and Bow­el Con­trol” on Tues­day, Jan. 10 at 6 p.m. to share more about the ther­a­py. Com­mu­ni­ty mem­bers are invit­ed to attend this free event. To reg­is­ter for the vir­tu­al talk, click here.

The Axon­ics Ther­a­py works by pro­vid­ing gen­tle elec­tri­cal stim­u­la­tion (sacral neu­ro­mod­u­la­tion) to the nerves that con­trol the blad­der and bow­el, restor­ing nor­mal com­mu­ni­ca­tion and result­ing in an improve­ment in symptoms.

The Axon­ics Sys­tem offers a long-lived minia­tur­ized neu­rostim­u­la­tor that is approx­i­mate­ly the size of a quar­ter. The recharge­able device is implant­ed into the pelvic area dur­ing a min­i­mal­ly inva­sive, out­pa­tient pro­ce­dure. It is qual­i­fied to last 15 or more years in the body, elim­i­nat­ing the need for repeat surg­eries over the patient’s life­time. Until today, the only oth­er prod­uct avail­able required replace­ment surgery every four years due to bat­tery deple­tion and removal of the implant­ed device if an MRI was required. Patients are pro­vid­ed with a dis­creet easy to use Remote Con­trol that can be used to man­age their therapy.

Ben­e­fits of Axon­ics Therapy

• Clin­i­cal­ly proven to help peo­ple regain uri­nary and bow­el con­trol²
• 93% of patients expe­ri­enc­ing clin­i­cal­ly sig­nif­i­cant symp­tom improve­ments at two years post-implant.²
• Designed to pro­vide patients with long-last­ing relief
• Allows patients to under­go Full-Body MRI safe­ly with­out hav­ing to explant the device
• High patient sat­is­fac­tion at 2 years²
  • 94% of patients were sat­is­fied with their ther­a­py²

Dr. Knud­son shared, ​“Blad­der con­trol issues can have a pro­found effect on a person’s qual­i­ty of life as well as have sig­nif­i­cant cost. Med­ica­tions do not help every­one or may have side effects. Axon­ics ther­a­py is a high­ly effec­tive option for many patients with by far the best cus­tomer ser­vice I have seen from any device company.”

Learn more at https://​www​.axon​ics​.com/.

Ref­er­ences:

1. Irwin DE, Kopp ZS, Agatep B, Mil­som I, Abrams P. World­wide preva­lence esti­mates of low­er uri­nary tract symp­toms, over­ac­tive blad­der, uri­nary incon­ti­nence and blad­der out­let obstruc­tion. BJU Int. 2011;108(7):1132 – 1138.
   2. Pezzel­la A, McCr­ery R, Lane F, et al. Two-year out­comes of the ARTI­SAN-SNM study for the

treat­ment of uri­nary urgency incon­ti­nence using the Axon­ics recharge­able sacral neu­ro­mod­u­la­tion sys­tem [in press]. Neu­rourol Uro­dyn. 2021.